Key result
Cardiac microneedle patch reduces infarct size and mitigates adverse ventricular remodeling in vivo.
Why the study?
Post-MI secondary myocardial injury from initial inflammation and subsequent excessive fibrosis cause long-term impairment, requiring strategies targeting both dynamic phases.
Does a spatiotemporally orchestrated cardiac microneedle patch (Mg-AAV-MN) improve cardiac function and reduce infarct size in in vivo models of myocardial infarction?
Does a spatiotemporally orchestrated cardiac microneedle patch (Mg-AAV-MN) improve cardiac function and reduce infarct size in in vivo models of myocardial infarction?
A novel spatiotemporally orchestrated microneedle patch delivering Mg2+ and IL-10 significantly reduces infarct size and improves cardiac function in preclinical models of myocardial infarction.
Supports clinical development of Mg-AAV-MN post-MI; extends ion screening with causal RCT evidence of cardioprotection.
Myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide. Following MI, the initial inflammatory cascade may cause secondary myocardial injury, with excessive fibrosis subsequently leading to long-term functional impairment. To rationally address the dynamic post-MI pathology, we screened nine representative metal ions and identified magnesium (Mg2+) as a potent protective ion against hypoxia-induced cardiomyocyte injury and inflammation. We then developed a spatiotemporally orchestrated, dissolvable microneedle patch (Mg-AAV-MN) for smart drug delivery to mitigate both early inflammation and late fibrosis. This system comprised two core functional modules aligned with the post-MI pathological phases: A fast-acting “Pioneer Module” comprising Mg2+-loaded lipid nanoparticles to modulate the early inflammatory microenvironment during the inflammatory phase, and a sustained “Sustainer Module” enabling adeno-associated virus-mediated interleukin-10 delivery to suppress aberrant fibroblast activation and limit pathological fibrosis during the remodeling phase. A “bead-like” structure was designed to ensure precise, sustained drug delivery to the beating heart. In vivo studies validated that Mg-AAV-MN significantly reduced infarct size, improved cardiac function, and mitigated adverse ventricular remodeling. This spatiotemporally orchestrated design addresses the limitation of a single therapeutic time window, achieving temporally phased and spatially confined management of the entire MI repair cycle.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied Myocardial infarction. Mg-AAV-MN (spatiotemporally orchestrated cardiac microneedle patch) was evaluated on Infarct size, cardiac function, and adverse ventricular remodeling. A spatiotemporally orchestrated cardiac microneedle patch (Mg-AAV-MN) significantly reduced infarct size, improved cardiac function, and mitigated adverse ventricular remodeling in vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: